The Cosmeceuticals Grey Zone: When a Cosmetic Claim Risks Becoming a Drug Claim

“Cosmeceutical” is a popular marketing word. It suggests something more powerful than an ordinary Cosmetic — a product that treats skin condition, not just improves appearance.

The problem is that Indian law does not recognize “Cosmeceutical” as a regulatory category at all. A product is either a Cosmetic or a Drug under the Drugs and Cosmetics Act, 1940, and the label a marketing team chooses does not decide which one it is. The claims made about the product do.

This article explains where that line sits and why getting it wrong is a bigger risk than it might first appear.

How the Law Defines a Cosmetic

Under Section 3(aaa) of the Drugs and Cosmetics Act, 1940, a Cosmetic is broadly defined as an article intended to be rubbed, poured, sprinkled, sprayed on, or otherwise applied to the human body for purposes like cleansing, beautifying, promoting attractiveness, or altering appearance. The Cosmetics Rules, 2020 operate within this same definition — the 2020 Rules did not change what counts as a Cosmetic; they modernized how Cosmetics are licensed, tested, and monitored.

A Drug, by contrast, is generally understood — under the same Act — as a substance intended for use in the diagnosis, treatment, mitigation, or prevention of disease, or intended to affect the structure or function of the body in a therapeutic sense.

The distinction, in plain language: a Cosmetic can clean, beautify, and improve appearance. A Drug treats, cures, prevents, or medically alters how the body functions. A single product can only occupy one category under Indian law — there is no in-between “Cosmeceutical” license.

Why “Cosmeceutical” Claims Are Risky

When a Cosmetic product is marketed using language that sounds like a Drug claim, it creates a mismatch between how the product is licensed and how it is being sold. Phrases that tend to push a product toward Drug territory include:

• Claims to “treat,” “cure,” or “heal” a named skin condition (such as acne, eczema, or

psoriasis)

• Claims to “prevent” a disease or medical condition

• Claims that the product changes the biological structure or function of the body in a therapeutic way, rather than a Cosmetic one
• Implying the product works like, or replaces, prescribed medical treatment

By contrast, claims that stay within the Cosmetic definition typically describe surface-level, Cosmetic effects — cleansing, moisturizing, improving the appearance of skin, reducing the visible look of a Cosmetic (not medical) concern.

The exact wording matters enormously. “Reduces the appearance of blemishes” sits differently from “clears acne.” “Improves the look of fine lines” sits differently from “reverses skin aging at the cellular level.” The second phrasing in each pair edges toward a therapeutic claim that a Cosmetic license does not cover.

Why This Matters Beyond Labeling

Getting this classification wrong is not just a labelling inconvenience. If a product marketed and sold as a Cosmetic is found, based on its claims, to function as a Drug, it may be treated as an unlicensed Drug — a far more serious regulatory position than a Cosmetic labeling issue. Cosmetics and Drugs are licensed through different processes, with different data requirements, and a product cannot borrow the lighter Cosmetic pathway while making claims that belong to the Drug pathway.

This is one of the most common areas where marketing ambition creates legal exposure. A formulation team may develop a product with genuine, measurable skin benefits, and a marketing team — trying to communicate that benefit persuasively — reaches for medical-sounding language that the product’s Cosmetic registration does not support.

Practical Guardrails

To stay within the Cosmetic classification while still communicating real product benefits:

• Avoid disease names in claims unless the product is separately licensed as a Drug. Refer to Cosmetic concerns (dullness, visible blemishes, dryness) rather than medical conditions (acne, dermatitis).
• Describe effects, not mechanisms of cure. “Helps reduce the visible appearance of X” is safer ground than “eliminates X” or “cures X.”
• Review claims together with regulatory affairs, not marketing alone. A claim that

reads well commercially should be checked against the Cosmetic-versus-Drug line before it goes on packaging or into an ad campaign.

• Be cautious with comparative claims to medical treatments. Language suggesting a product works “as well as” or “instead of” a prescribed treatment strongly implies a therapeutic function.
• Treat “Cosmeceutical” as a marketing word only, internally. Use it in brand storytelling if you must but never let it substitute for a genuine internal check of what the actual claims say.

Summary

The appeal of a “Cosmeceutical” positioning is understandable — it promises the credibility of medicine with the ease of a Cosmetic launch. But Indian regulation does not offer that middle ground. The safest approach is to decide, early and deliberately, which category a product belongs in, and then keep every claim — on the label, on the website, and in advertising — consistent with that choice.

This closes the first four articles in our updated Cosmetics series. Together, they cover the areas where feedback showed the earlier series needed more clarity: how post-market obligations work in practice, what evidence claims require, how a safety dossier for a novel ingredient is built, and where Cosmetic claims risk crossing into Drug territory. The next set of four will move into cross-border compliance, GMP audit readiness, and e-commerce-specific requirements.

Conclusion

• India does not recognize “Cosmeceutical” as a separate regulatory category. 
• Product classification depends on its intended use and claims, not marketing terminology. 
• Claims to treat, cure, prevent, or mitigate diseases may move a product toward Drug classification. 
• Cosmetic claims should focus on cleansing, beautifying, moisturizing, and improving appearance. 
• Disease-related, therapeutic, and medical-treatment claims require careful regulatory review. 
• Claims should be assessed before appearing on labels, websites, advertisements, or promotional materials. 
• Early regulatory review helps minimize classification, compliance, and enforcement risks.